{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:12:02Z","timestamp":1787508722318,"version":"build-2736575974"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with concurrent malignancies pose significant diagnostic and therapeutic challenges. We report a rare and fatal case of synchronous ovarian mixed germ cell tumor and mast cell leukemia (MCL) in a 13-year-old female, characterized by a shared clonal origin. The patient initially presented with a large pelvic mass, elevated alpha-fetoprotein(AFP) and human chorionic gonadotropin (\u03b2-HCG), anemia, and thrombocytopenia. Exploratory laparotomy confirmed a diagnosis of mixed germ cell tumor, predominantly dysgerminoma with a minor choriocarcinoma component. Despite an initial decrease in serum tumor markers to platinum-based chemotherapy, persistent cytopenias and bone marrow infiltration raised concern for hematologic malignancy. Genomic analyses of both ovarian tumor and bone marrow samples identified identical somatic mutations, including KIT D816V, NRAS G12C and TP53 Y220C, strongly suggesting a common progenitor. Subsequent immunophenotyping, histology, and transcriptome sequencing confirmed the diagnosis of concurrent mast cell leukemia. Targeted therapy with avapritinib and ruxolitinib was initiated but yielded limited response. Further salvage therapy failed due to disease progression and treatment intolerance, and the patient succumbed to multiple organ failure. This case underscores the clinical and genetic overlap between germ cell tumors and hematological malignancies in pediatric patients, highlighting the role of KIT mutations as a potential unifying driver. Given the consistent co-occurrence of KIT mutations in previously reported similar cases, we propose the recognition of a distinct disease entity: ovarian germ cell tumor\/mastocytosis with KIT mutations. This report emphasizes the importance of early genetic profiling and multidisciplinary collaboration in diagnosing and managing rare, genetically unified malignancies in pediatric oncology.<\/jats:p>","DOI":"10.3389\/fonc.2025.1717065","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:20:04Z","timestamp":1767676804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A rare case of synchronous ovarian mixed germ cell tumor and mast cell leukemia in a pediatric patient"],"prefix":"10.3389","volume":"15","author":[{"given":"Chengzhu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songji","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23000","article-title":"Ovarian germ cell tumor\/mastocytosis with KIT mutation: A unique clinicopathological entity","volume":"61","author":"Xiao","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04322.x","article-title":"Cutaneous mastocytosis associated with a mixed germ cell tumour of the ovary: report of a case and review of the literature","volume":"145","author":"Miyagawa","year":"2001","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10816.x","article-title":"N822K c-kit mutation in CD30-positive cutaneous pleomorphic mastocytosis after germ cell tumour of the ovary","volume":"166","author":"Baek","year":"2012","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e26282","DOI":"10.1002\/pbc.26282","article-title":"A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia","volume":"64","author":"Mitchell","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27655","article-title":"TP53-mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shah","year":"2025","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e240030","DOI":"10.6004\/jnccn.2024.0030","article-title":"NCCN guidelines\u00ae Insights: systemic mastocytosis, version 3.2024","volume":"22","author":"Gotlib","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: A consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"B8","doi-asserted-by":"publisher","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-031521-042618","article-title":"New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy","volume":"18","author":"Valent","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1476-4598-6-12","article-title":"Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers","volume":"6","author":"Hoei-Hansen","year":"2007","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139682","article-title":"Germ cell tumors and associated hematologic Malignancies evolve from a common shared precursor","volume":"130","author":"Taylor","year":"2020","journal-title":"J Clin Investig"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.3390\/ijms222111774","article-title":"The role of TP53 in cisplatin resistance in mediastinal and testicular germ cell tumors","volume":"22","author":"Timmerman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2868","article-title":"Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors","volume":"20","author":"Feldman","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008292","article-title":"Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry","volume":"7","author":"Kennedy","year":"2023","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/ng.3466","article-title":"Exploring genomic alteration in pediatric cancer using protein-paint","volume":"48","author":"Zhou","year":"2016","journal-title":"Nat Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1717065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:20:07Z","timestamp":1767676807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1717065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":17,"alternative-id":["10.3389\/fonc.2025.1717065"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1717065","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1717065"}}